Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

Critical Care Medicine

Volumn 40, Issue 1, 2012, Pages 104-111

  Froissart, Antoine ^a   Buffet, Marc ^b   Veyradier, Agnès ^c   Poullin, Pascale ^d   Provôt, François ^e   Malot, Sandrine ^b   Schwarzinger, Michael ^f   Galicier, Lionel ^g   Vanhille, Philippe ⁱ   Vernant, Jean Paul ^a   Bordessoule, Dominique ^j   Guidet, Bertrand ^a   Azoulay, Elie ^h   Mariotte, Eric ^h   Rondeau, Eric ^a   Mira, Jean Paul ^k   Wynckel, Alain ^l   Clabault, Karine ^m   Choukroun, Gabriel ⁿ   Presne, Claire ⁿ   Pourrat, Jacques ^o   Hamidou, Mohamed ^p   Coppo, Paul ^b   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Service d'Hématologie Greffe HÔpital Saint Louis   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

^g Service d'Immunopathologie   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER DE VALENCIENNES   (France)

^j DUPUYTREN UNIVERSITY HOSPITAL   (France)

^k CHU Dupuytren ^*  (France)

^l HÔPITAL MAISON BLANCHE   (France)

^m HÔPITAL CHARLES NICOLLE   (France)

ⁿ AMIENS UNIVERSITY HOSPITAL   (France)

^o CHU RANGUEIL   (France)

^p HÔTEL DIEU   (France)

more..

Author keywords

Cardiac disorder; Coma; Hemolytic uremic syn drome; Rescue therapy; Thrombosis; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

CYCLOPHOSPHAMIDE; ENZYME ANTIBODY; GLUCOCORTICOID; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; B CELL DEPLETION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRANCE; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTIOUS COMPLICATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE DEPLETION; MALE; OPEN STUDY; PLASMA VOLUME; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SURVIVOR; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84055166960     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31822e9d66     Document Type: Article

References (26)

1. Terrell DR, Williams LA, Vesely SK, et al: The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3:1432-1436
2. Klaus C, Plaimauer B, Studt JD, et al: Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-4519
3. Scheiflinger F, Knöbl P, Trattner B, et al: Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102:3241-3243
4. Sadler JE: Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112:11-18
5. Veyradier A, Obert B, Houllier A, et al: Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001; 98: 1765-1772
6. Hovinga JA, Vesely SK, Terrell DR, et al: Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500-1511; quiz 1662
7. Coppo P, Bengoufa D, Veyradier A, et al: Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004; 83:233-244
8. Shelat SG, Smith P, Ai J, et al: Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006; 4:1707-1717
9. Ferrari S, Scheiflinger F, Rieger M, et al: Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109:2815-2822
10. Zheng XL, Kaufman RM, Goodnough LT, et al: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103:4043-4049
11. Rastetter W, Molina A, White CA: Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004; 55:477-503
12. Godeau B, Porcher R, Fain O, et al: Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004
13. Gutterman LA, Kloster B, Tsai HM: Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002; 28:385-391
14. Fakhouri F, Vernant JP, Veyradier A, et al: Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 2005; 106: 1932-1937
15. Scully M, Cohen H, Cavenagh J, et al: Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136:451-461
16. Elliott MA, Heit JA, Pruthi RK, et al: Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: A report of four cases and a systematic review of the literature. Eur J Haematol 2009; 83:365-372
17. Coppo P, Schwarzinger M, Buffet M, et al: Predictive features of severe acquired ADAMTS13 deficiency in idiopathic throm-botic microangiopathies: The French TMA reference center experience. PLoS One 2010; 5:e10208
18. Coppo P, Wolf M, Veyradier A, et al: Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006; 132:66-74
19. Patton JF, Manning KR, Case D, et al: Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. Am J Hematol 1994; 47: 94-99
20. Howard MA, Williams LA, Terrell DR, et al: Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006; 46: 154-156
21. Darabi K, Berg AH: Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006; 125:592-597
22. Sidner RA, Book BK, Agarwal A, et al: In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13:55-62
23. Peyvandi F, Lavoretano S, Palla R, et al: ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93:232-239
24. Tamimoto Y, Horiuchi T, Tsukamoto H, et al: A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: Immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 2008; 47:821-827
25. McDonald V, Manns K, Mackie IJ, et al: Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8:1201-1208
26. Carson KR, Evens AM, Richey EA, et al: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840